arrow
M

Marta Bonotto

academic hospital of udine asufc
H指数:22
被引数:1,638

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics

激素受体阳性、HER2阴性转移性乳腺癌的纵向表型分析:基于液滴数字PCR的循环肿瘤DNA片段组学研究

2025-07-020
PRE
Differential dynamics of fragmentomic and epigenetic circulating tumor DNA (ctDNA) features in first-line Palbociclib and Ribociclib treatment for Hormone Receptor (HR) positive, HER2 negative metastatic breast cancer (MBC)
2024-05-020
PRE
Unraveling the influence of progesterone receptor status on endocrine therapy sensitivity: insight from epigenetic and fragmentomics ctDNA profiling in estrogen receptor positive, HER2 negative metastatic breast cancer (MBC)
2024-05-020
PRE
Cell-free DNA (cfDNA) workflow for the risk definition of dose-limiting and recurrent neutropenia in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC)
2021-09-010
OAAI
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study

激素受体 (HR) 阳性HER2-negative转移性乳腺癌的一线和二线治疗策略: 一项真实世界研究

BREAST
IF7.9
2021-06-0121
OAAI
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
2021-04-0112
OAAI
The SENECA study: Prognostic role of serum biomarkers in older patients with metastatic colorectal cancer
2020-11-019
PREAI
Plasma-Based Longitudinal Evaluation ofESR1Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer

基于血浆的激素受体阳性HER2-Negative转移性乳腺癌esr1表观遗传状态的纵向评估

2020-09-1821
OAAI
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis
2020-04-2416
OAAI